Advertisement


Matteo Lambertini, MD, on Pregnancy in Breast Cancer Patients: Results From a Multicenter Study

2017 ASCO Annual Meeting

Advertisement

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses a long-term follow-up analysis of the safety of pregnancy in patients with a history of estrogen receptor–positive breast cancer. (Abstract LBA10066)



Related Videos

Head and Neck Cancer
Issues in Oncology

Maura L. Gillison, MD, PhD, on HPV and the Value of the Vaccine

Maura L. Gillison, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the impact of prophylactic human papillomavirus vaccination on oral HPV infections among young adults in the United States. (Abstract 6003)

Prostate Cancer

Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial

Nicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy (Abstract LBA5003).

Prostate Cancer

Neeraj Agarwal, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on the LATITUDE Trial

Neeraj Agarwal, MD, of Huntsman Cancer Institute, and Sumanta K. Pal, MD, of the City of Hope, examine the study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)

Issues in Oncology

Lee S. Schwartzberg, MD: 2017 Update on ICLIO: Adopting Immunotherapy in the Community Setting

Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.

Prostate Cancer

Gerhardt Attard, MD, PhD, on Prostate Cancer: Results From an After-Market Study on Enzalutamide

Gerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)

Advertisement

Advertisement




Advertisement